| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 62 | 2023 | 2274 | 4.850 |
Why?
|
| Thyroidectomy | 38 | 2023 | 877 | 3.300 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 18 | 2020 | 46 | 3.270 |
Why?
|
| Adrenocortical Carcinoma | 11 | 2022 | 88 | 3.230 |
Why?
|
| Adrenal Cortex Neoplasms | 11 | 2022 | 162 | 3.160 |
Why?
|
| Carcinoma, Papillary | 20 | 2018 | 781 | 2.430 |
Why?
|
| General Surgery | 19 | 2019 | 1633 | 2.240 |
Why?
|
| Adrenalectomy | 16 | 2018 | 342 | 1.890 |
Why?
|
| Lymph Node Excision | 12 | 2022 | 1248 | 1.750 |
Why?
|
| Specialties, Surgical | 8 | 2018 | 389 | 1.670 |
Why?
|
| Neck Dissection | 9 | 2014 | 196 | 1.540 |
Why?
|
| Parathyroid Glands | 13 | 2017 | 509 | 1.480 |
Why?
|
| Thyroid Gland | 13 | 2020 | 1172 | 1.300 |
Why?
|
| Iodine Radioisotopes | 10 | 2014 | 1030 | 1.240 |
Why?
|
| Adrenal Gland Neoplasms | 14 | 2018 | 740 | 1.210 |
Why?
|
| Parathyroidectomy | 15 | 2016 | 235 | 1.180 |
Why?
|
| Hyperparathyroidism | 15 | 2016 | 339 | 1.180 |
Why?
|
| Duodenal Neoplasms | 6 | 2020 | 106 | 1.140 |
Why?
|
| Neuroendocrine Tumors | 8 | 2013 | 594 | 1.090 |
Why?
|
| Education, Medical, Graduate | 8 | 2018 | 2283 | 1.060 |
Why?
|
| Carcinoma | 14 | 2018 | 2374 | 1.000 |
Why?
|
| Thyroglobulin | 5 | 2014 | 114 | 0.990 |
Why?
|
| Surgical Procedures, Operative | 7 | 2020 | 1873 | 0.900 |
Why?
|
| Pancreatic Neoplasms | 21 | 2020 | 5249 | 0.890 |
Why?
|
| Interferon-gamma | 14 | 2007 | 3199 | 0.890 |
Why?
|
| Thyroid Nodule | 10 | 2022 | 750 | 0.870 |
Why?
|
| Parathyroid Neoplasms | 7 | 2018 | 245 | 0.820 |
Why?
|
| Thyroid Diseases | 5 | 2020 | 378 | 0.800 |
Why?
|
| Laparoscopy | 13 | 2018 | 2121 | 0.800 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2021 | 325 | 0.750 |
Why?
|
| Physicians, Women | 4 | 2020 | 487 | 0.750 |
Why?
|
| Endocrine Glands | 1 | 2020 | 103 | 0.710 |
Why?
|
| Hyperaldosteronism | 4 | 2021 | 239 | 0.700 |
Why?
|
| Internship and Residency | 13 | 2020 | 5774 | 0.700 |
Why?
|
| Faculty, Medical | 3 | 2020 | 1182 | 0.690 |
Why?
|
| Parathyroid Hormone | 13 | 2023 | 1801 | 0.670 |
Why?
|
| Monitoring, Intraoperative | 8 | 2016 | 953 | 0.660 |
Why?
|
| Lymphatic Metastasis | 14 | 2022 | 2906 | 0.620 |
Why?
|
| Child Care | 1 | 2018 | 119 | 0.600 |
Why?
|
| Endocrine Surgical Procedures | 2 | 2015 | 33 | 0.580 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2018 | 9185 | 0.570 |
Why?
|
| Pheochromocytoma | 6 | 2012 | 337 | 0.550 |
Why?
|
| Humans | 223 | 2024 | 742088 | 0.540 |
Why?
|
| Interferon Regulatory Factor-2 | 6 | 2005 | 23 | 0.530 |
Why?
|
| Home Care Services | 1 | 2022 | 602 | 0.520 |
Why?
|
| Phosphoproteins | 5 | 2003 | 2440 | 0.520 |
Why?
|
| Adenocarcinoma, Follicular | 3 | 2018 | 324 | 0.520 |
Why?
|
| Interferon Regulatory Factor-1 | 6 | 2005 | 68 | 0.510 |
Why?
|
| Vocal Cord Paralysis | 2 | 2017 | 267 | 0.510 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 5 | 2008 | 44 | 0.500 |
Why?
|
| Neoplasm Staging | 23 | 2022 | 11001 | 0.470 |
Why?
|
| Endocrinology | 6 | 2020 | 443 | 0.460 |
Why?
|
| Parathyroid Diseases | 2 | 2010 | 48 | 0.460 |
Why?
|
| Repressor Proteins | 5 | 2003 | 3020 | 0.460 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2015 | 277 | 0.450 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 1369 | 0.450 |
Why?
|
| Adenoma | 8 | 2023 | 2168 | 0.450 |
Why?
|
| Career Choice | 2 | 2018 | 743 | 0.440 |
Why?
|
| Vipoma | 3 | 2010 | 7 | 0.430 |
Why?
|
| Carcinoid Tumor | 2 | 2013 | 235 | 0.420 |
Why?
|
| Mentors | 2 | 2018 | 630 | 0.420 |
Why?
|
| Hypoparathyroidism | 2 | 2010 | 120 | 0.420 |
Why?
|
| Insulinoma | 5 | 2005 | 124 | 0.400 |
Why?
|
| Hypocalcemia | 2 | 2023 | 191 | 0.400 |
Why?
|
| Gallbladder Neoplasms | 1 | 2013 | 183 | 0.390 |
Why?
|
| Specialization | 1 | 2016 | 777 | 0.380 |
Why?
|
| Peptones | 1 | 2010 | 5 | 0.380 |
Why?
|
| Cell Transdifferentiation | 1 | 2011 | 171 | 0.370 |
Why?
|
| Emergencies | 1 | 2017 | 1164 | 0.370 |
Why?
|
| Burnout, Professional | 1 | 2019 | 690 | 0.370 |
Why?
|
| Somatostatinoma | 2 | 2010 | 10 | 0.370 |
Why?
|
| Glucagonoma | 2 | 2010 | 14 | 0.370 |
Why?
|
| Female | 123 | 2022 | 379592 | 0.360 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 941 | 0.360 |
Why?
|
| Horner Syndrome | 1 | 2009 | 37 | 0.350 |
Why?
|
| Liver Neoplasms | 6 | 2013 | 4249 | 0.350 |
Why?
|
| Cushing Syndrome | 6 | 2011 | 249 | 0.340 |
Why?
|
| DNA-Binding Proteins | 6 | 2003 | 9639 | 0.340 |
Why?
|
| Surgery Department, Hospital | 2 | 2020 | 175 | 0.340 |
Why?
|
| Societies, Medical | 4 | 2019 | 3740 | 0.340 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2022 | 701 | 0.330 |
Why?
|
| Clinical Competence | 7 | 2019 | 4681 | 0.330 |
Why?
|
| Middle Aged | 87 | 2022 | 213127 | 0.320 |
Why?
|
| Attitude of Health Personnel | 3 | 2018 | 3839 | 0.320 |
Why?
|
| Activins | 1 | 2009 | 208 | 0.320 |
Why?
|
| Nerve Compression Syndromes | 1 | 2009 | 161 | 0.310 |
Why?
|
| Male | 96 | 2022 | 349538 | 0.300 |
Why?
|
| Adult | 79 | 2021 | 213712 | 0.300 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 3611 | 0.300 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2008 | 648 | 0.300 |
Why?
|
| Transcription Factors | 7 | 2018 | 12164 | 0.300 |
Why?
|
| Career Mobility | 2 | 2020 | 262 | 0.300 |
Why?
|
| Tumor Necrosis Factor-alpha | 13 | 2004 | 4414 | 0.290 |
Why?
|
| Adenoma, Islet Cell | 4 | 1998 | 82 | 0.280 |
Why?
|
| Sarcoma, Experimental | 2 | 1997 | 128 | 0.280 |
Why?
|
| Postoperative Complications | 18 | 2023 | 15244 | 0.280 |
Why?
|
| Ultrasonography | 10 | 2019 | 5978 | 0.280 |
Why?
|
| Reoperation | 9 | 2018 | 4200 | 0.280 |
Why?
|
| Thymus Gland | 1 | 2011 | 1264 | 0.280 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2006 | 60 | 0.280 |
Why?
|
| Hyperparathyroidism, Primary | 4 | 2013 | 155 | 0.280 |
Why?
|
| Aged | 66 | 2021 | 162944 | 0.280 |
Why?
|
| Emergency Medical Services | 2 | 2015 | 1914 | 0.280 |
Why?
|
| Carcinoma, Islet Cell | 2 | 2003 | 22 | 0.270 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2013 | 987 | 0.270 |
Why?
|
| Biopsy, Needle | 8 | 2011 | 1640 | 0.270 |
Why?
|
| Biopsy, Fine-Needle | 9 | 2020 | 1093 | 0.270 |
Why?
|
| Lymph Nodes | 9 | 2021 | 3465 | 0.260 |
Why?
|
| Genetic Engineering | 1 | 2011 | 952 | 0.260 |
Why?
|
| Gastrinoma | 2 | 2003 | 21 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 9 | 2021 | 3612 | 0.250 |
Why?
|
| Preoperative Care | 6 | 2016 | 2245 | 0.250 |
Why?
|
| Prognosis | 26 | 2023 | 29010 | 0.240 |
Why?
|
| Retrospective Studies | 44 | 2022 | 77098 | 0.240 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2023 | 2028 | 0.240 |
Why?
|
| Radionuclide Imaging | 8 | 2018 | 2027 | 0.240 |
Why?
|
| Internet | 2 | 2015 | 3062 | 0.240 |
Why?
|
| Endotoxins | 5 | 1992 | 525 | 0.240 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2003 | 25 | 0.240 |
Why?
|
| Tissue Array Analysis | 1 | 2005 | 553 | 0.230 |
Why?
|
| Breast Neoplasms | 12 | 2010 | 20774 | 0.230 |
Why?
|
| Medicaid | 1 | 2016 | 2716 | 0.230 |
Why?
|
| Combined Modality Therapy | 11 | 2017 | 8621 | 0.230 |
Why?
|
| United States | 27 | 2021 | 69693 | 0.220 |
Why?
|
| Cell Differentiation | 6 | 2016 | 11470 | 0.220 |
Why?
|
| Pregnancy | 4 | 2018 | 29087 | 0.220 |
Why?
|
| Relief Work | 1 | 2024 | 137 | 0.210 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2022 | 88 | 0.210 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 57683 | 0.210 |
Why?
|
| Embryonic Stem Cells | 1 | 2009 | 1294 | 0.200 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 1618 | 0.200 |
Why?
|
| Vitamin D Deficiency | 2 | 2023 | 1331 | 0.200 |
Why?
|
| Quality of Health Care | 2 | 2016 | 4369 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 10 | 2020 | 7276 | 0.200 |
Why?
|
| Gastric Bypass | 1 | 2010 | 812 | 0.200 |
Why?
|
| Adenocarcinoma | 6 | 2023 | 6347 | 0.200 |
Why?
|
| Teaching | 1 | 2009 | 1174 | 0.190 |
Why?
|
| Receptors, Somatostatin | 2 | 1998 | 129 | 0.190 |
Why?
|
| Graves Disease | 2 | 2013 | 241 | 0.190 |
Why?
|
| Financial Management, Hospital | 1 | 2021 | 74 | 0.190 |
Why?
|
| Cell Division | 4 | 2003 | 4564 | 0.190 |
Why?
|
| Treatment Outcome | 28 | 2020 | 62966 | 0.190 |
Why?
|
| Octreotide | 2 | 1998 | 145 | 0.180 |
Why?
|
| Terminology as Topic | 2 | 2018 | 1548 | 0.180 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 1097 | 0.180 |
Why?
|
| Pancreatectomy | 4 | 2009 | 802 | 0.180 |
Why?
|
| Neoplasm Metastasis | 7 | 2020 | 4839 | 0.180 |
Why?
|
| Oncogene Proteins | 2 | 2005 | 749 | 0.180 |
Why?
|
| Obesity, Morbid | 1 | 2010 | 1204 | 0.170 |
Why?
|
| Survival Analysis | 7 | 2013 | 10248 | 0.170 |
Why?
|
| Recurrent Laryngeal Nerve | 2 | 2016 | 139 | 0.170 |
Why?
|
| Quarantine | 1 | 2021 | 167 | 0.170 |
Why?
|
| Radiation Injuries | 1 | 2006 | 1178 | 0.170 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 2749 | 0.170 |
Why?
|
| Interleukin-1 | 6 | 1995 | 1262 | 0.170 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2002 | 1101 | 0.170 |
Why?
|
| Pentetic Acid | 1 | 1998 | 213 | 0.160 |
Why?
|
| Diagnosis-Related Groups | 3 | 2016 | 454 | 0.160 |
Why?
|
| Postoperative Care | 6 | 2014 | 1484 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2018 | 600 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2013 | 1769 | 0.160 |
Why?
|
| Length of Stay | 6 | 2018 | 6294 | 0.160 |
Why?
|
| Interprofessional Relations | 3 | 2019 | 1008 | 0.160 |
Why?
|
| Medical Oncology | 4 | 2016 | 2235 | 0.160 |
Why?
|
| Survival Rate | 8 | 2013 | 12773 | 0.160 |
Why?
|
| Radiopharmaceuticals | 5 | 2022 | 2658 | 0.160 |
Why?
|
| Job Satisfaction | 2 | 2018 | 535 | 0.160 |
Why?
|
| SEER Program | 3 | 2017 | 1507 | 0.150 |
Why?
|
| Adolescent | 25 | 2019 | 85649 | 0.150 |
Why?
|
| Neck | 5 | 2012 | 693 | 0.150 |
Why?
|
| Carcinoma in Situ | 2 | 2001 | 802 | 0.150 |
Why?
|
| Paget's Disease, Mammary | 1 | 1997 | 19 | 0.150 |
Why?
|
| Risk Assessment | 11 | 2019 | 23320 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2012 | 3471 | 0.150 |
Why?
|
| Laryngoplasty | 1 | 2017 | 53 | 0.150 |
Why?
|
| Interdisciplinary Communication | 2 | 2014 | 950 | 0.150 |
Why?
|
| Consensus | 3 | 2023 | 2935 | 0.150 |
Why?
|
| Sarcopenia | 2 | 2012 | 368 | 0.140 |
Why?
|
| Trans-Activators | 2 | 2003 | 2924 | 0.140 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2018 | 145 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2005 | 8425 | 0.140 |
Why?
|
| Guidelines as Topic | 3 | 2019 | 1402 | 0.140 |
Why?
|
| Zollinger-Ellison Syndrome | 4 | 2009 | 15 | 0.140 |
Why?
|
| Immunohistochemistry | 11 | 2011 | 11363 | 0.140 |
Why?
|
| Infection Control | 2 | 2020 | 962 | 0.140 |
Why?
|
| Awards and Prizes | 1 | 2020 | 375 | 0.140 |
Why?
|
| Hydrocortisone | 4 | 2011 | 1825 | 0.140 |
Why?
|
| Depression | 1 | 2015 | 7733 | 0.140 |
Why?
|
| Melanoma, Experimental | 1 | 1999 | 559 | 0.130 |
Why?
|
| Follow-Up Studies | 17 | 2018 | 39004 | 0.130 |
Why?
|
| Lipopolysaccharides | 6 | 2002 | 2211 | 0.130 |
Why?
|
| Patients | 1 | 2022 | 892 | 0.130 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2018 | 503 | 0.130 |
Why?
|
| Medical Staff, Hospital | 2 | 2016 | 603 | 0.130 |
Why?
|
| Psoas Muscles | 2 | 2012 | 71 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2021 | 980 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2016 | 499 | 0.120 |
Why?
|
| ras Proteins | 1 | 2020 | 1060 | 0.120 |
Why?
|
| Malpractice | 1 | 2019 | 569 | 0.120 |
Why?
|
| Stereotaxic Techniques | 1 | 1996 | 535 | 0.120 |
Why?
|
| Intra-Abdominal Fat | 3 | 2018 | 591 | 0.120 |
Why?
|
| Michigan | 3 | 2010 | 350 | 0.120 |
Why?
|
| Thymus Hyperplasia | 1 | 2013 | 30 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 3510 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2018 | 4211 | 0.110 |
Why?
|
| Triage | 1 | 2020 | 977 | 0.110 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2017 | 334 | 0.110 |
Why?
|
| Interinstitutional Relations | 1 | 2014 | 240 | 0.110 |
Why?
|
| Neoplasms, Experimental | 2 | 1996 | 1274 | 0.110 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 284 | 0.110 |
Why?
|
| Decision Support Techniques | 2 | 2014 | 1952 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2018 | 20086 | 0.110 |
Why?
|
| beta Catenin | 1 | 2018 | 1058 | 0.110 |
Why?
|
| Nicardipine | 1 | 2012 | 59 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2005 | 4553 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2020 | 1188 | 0.110 |
Why?
|
| Hospitals | 3 | 2022 | 3937 | 0.110 |
Why?
|
| Magnesium Sulfate | 1 | 2012 | 68 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 1327 | 0.110 |
Why?
|
| Postoperative Period | 3 | 2017 | 1839 | 0.110 |
Why?
|
| Risk Adjustment | 1 | 2016 | 594 | 0.110 |
Why?
|
| Social Behavior | 1 | 2019 | 1128 | 0.110 |
Why?
|
| Physician's Role | 2 | 2016 | 942 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2502 | 0.110 |
Why?
|
| STAT1 Transcription Factor | 2 | 2003 | 320 | 0.110 |
Why?
|
| Patient Selection | 3 | 2020 | 4214 | 0.100 |
Why?
|
| Medical Informatics | 1 | 2019 | 742 | 0.100 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 5304 | 0.100 |
Why?
|
| Goiter | 2 | 2010 | 86 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 2107 | 0.100 |
Why?
|
| Receptors, Thyrotropin | 1 | 2011 | 45 | 0.100 |
Why?
|
| Endosonography | 3 | 2005 | 610 | 0.100 |
Why?
|
| Population Surveillance | 2 | 2016 | 2616 | 0.100 |
Why?
|
| Pentoxifylline | 1 | 1991 | 55 | 0.100 |
Why?
|
| Appendectomy | 1 | 2014 | 400 | 0.100 |
Why?
|
| Calcium | 5 | 2023 | 5753 | 0.100 |
Why?
|
| Diagnosis, Differential | 7 | 2017 | 12958 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 2938 | 0.100 |
Why?
|
| Time Factors | 15 | 2021 | 40054 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2015 | 692 | 0.100 |
Why?
|
| Access to Information | 1 | 2014 | 320 | 0.100 |
Why?
|
| Voice | 2 | 2013 | 259 | 0.100 |
Why?
|
| Patient Preference | 1 | 2018 | 886 | 0.100 |
Why?
|
| Databases, Factual | 6 | 2018 | 7716 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 6 | 2003 | 6313 | 0.100 |
Why?
|
| Cholecystectomy | 1 | 2013 | 387 | 0.100 |
Why?
|
| Endoderm | 1 | 2011 | 150 | 0.090 |
Why?
|
| Risk | 3 | 2019 | 9679 | 0.090 |
Why?
|
| Interleukin-6 | 5 | 2011 | 3199 | 0.090 |
Why?
|
| Fibroblasts | 2 | 2011 | 4143 | 0.090 |
Why?
|
| Leadership | 1 | 2020 | 1357 | 0.090 |
Why?
|
| Self Report | 2 | 2018 | 3548 | 0.090 |
Why?
|
| Mutation | 5 | 2023 | 29717 | 0.090 |
Why?
|
| Carcinoma, Ductal | 1 | 2010 | 101 | 0.090 |
Why?
|
| Paraganglioma | 1 | 2011 | 143 | 0.090 |
Why?
|
| Cervical Plexus | 1 | 2009 | 12 | 0.090 |
Why?
|
| Perception | 1 | 2016 | 1188 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3691 | 0.090 |
Why?
|
| Child | 14 | 2020 | 77478 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 2 | 2013 | 744 | 0.090 |
Why?
|
| Mitotane | 1 | 2009 | 18 | 0.090 |
Why?
|
| Metanephrine | 1 | 2009 | 26 | 0.090 |
Why?
|
| Communication | 1 | 2023 | 3728 | 0.090 |
Why?
|
| Carcinoma, Medullary | 1 | 2010 | 123 | 0.090 |
Why?
|
| Heparin | 1 | 2017 | 1636 | 0.090 |
Why?
|
| Thyroid Hormones | 1 | 2012 | 390 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2018 | 2968 | 0.090 |
Why?
|
| Calcium Channel Blockers | 1 | 2012 | 689 | 0.090 |
Why?
|
| Hepatectomy | 1 | 2013 | 550 | 0.090 |
Why?
|
| Ablation Techniques | 1 | 2012 | 249 | 0.080 |
Why?
|
| Young Adult | 10 | 2020 | 56350 | 0.080 |
Why?
|
| Cell Adhesion | 2 | 2011 | 3139 | 0.080 |
Why?
|
| Splenectomy | 2 | 2008 | 395 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2016 | 1827 | 0.080 |
Why?
|
| Goiter, Substernal | 1 | 2008 | 17 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 6754 | 0.080 |
Why?
|
| Intraoperative Care | 1 | 2012 | 766 | 0.080 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2008 | 29 | 0.080 |
Why?
|
| Mediastinal Neoplasms | 1 | 1992 | 421 | 0.080 |
Why?
|
| Perioperative Care | 2 | 2016 | 997 | 0.080 |
Why?
|
| Adiposity | 1 | 2018 | 1806 | 0.080 |
Why?
|
| Antigens, Differentiation | 2 | 2009 | 926 | 0.080 |
Why?
|
| Catecholamines | 1 | 2009 | 387 | 0.080 |
Why?
|
| Orbit | 1 | 2011 | 427 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 6534 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 2885 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2022 | 2013 | 0.080 |
Why?
|
| Quality Improvement | 3 | 2023 | 3738 | 0.080 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 3070 | 0.080 |
Why?
|
| Parental Leave | 2 | 2018 | 78 | 0.080 |
Why?
|
| Hormones | 1 | 1992 | 884 | 0.080 |
Why?
|
| Patient Readmission | 2 | 2020 | 3111 | 0.080 |
Why?
|
| Antibodies | 5 | 1999 | 2459 | 0.080 |
Why?
|
| Mothers | 1 | 2018 | 2163 | 0.080 |
Why?
|
| Laryngoscopy | 1 | 2013 | 706 | 0.080 |
Why?
|
| Emergency Treatment | 1 | 2011 | 517 | 0.080 |
Why?
|
| Decision Making | 3 | 2020 | 3869 | 0.080 |
Why?
|
| Mice | 19 | 2010 | 81045 | 0.080 |
Why?
|
| Pituitary-Adrenal System | 1 | 1990 | 553 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 974 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2013 | 13655 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 1066 | 0.070 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2008 | 152 | 0.070 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 839 | 0.070 |
Why?
|
| Pandemics | 3 | 2023 | 8328 | 0.070 |
Why?
|
| Organizational Objectives | 1 | 2009 | 438 | 0.070 |
Why?
|
| Age Distribution | 2 | 2005 | 2900 | 0.070 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 1162 | 0.070 |
Why?
|
| Intraoperative Period | 3 | 2017 | 520 | 0.070 |
Why?
|
| Patient Advocacy | 1 | 2009 | 353 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2018 | 5310 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2018 | 576 | 0.070 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1990 | 703 | 0.070 |
Why?
|
| Physician Assistants | 1 | 2009 | 193 | 0.070 |
Why?
|
| Positron-Emission Tomography | 4 | 2022 | 6259 | 0.070 |
Why?
|
| Robotics | 1 | 2014 | 892 | 0.070 |
Why?
|
| Duodenum | 1 | 2009 | 483 | 0.070 |
Why?
|
| Respiratory Sounds | 1 | 2010 | 693 | 0.070 |
Why?
|
| Recombinant Proteins | 9 | 2003 | 6608 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 12 | 2002 | 21821 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 7770 | 0.070 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2016 | 1208 | 0.070 |
Why?
|
| Incidence | 5 | 2015 | 20928 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 484 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2012 | 3913 | 0.070 |
Why?
|
| Overweight | 2 | 2023 | 2366 | 0.070 |
Why?
|
| Accreditation | 1 | 2009 | 449 | 0.070 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 7645 | 0.070 |
Why?
|
| Recurrence | 4 | 2014 | 8333 | 0.070 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 2 | 2002 | 10 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 4229 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3215 | 0.070 |
Why?
|
| Patient Care Team | 2 | 2014 | 2527 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2015 | 2049 | 0.070 |
Why?
|
| Transplantation, Heterotopic | 1 | 2005 | 175 | 0.070 |
Why?
|
| Transplantation, Autologous | 1 | 2010 | 2123 | 0.070 |
Why?
|
| Animals | 23 | 2011 | 168561 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2266 | 0.070 |
Why?
|
| Registries | 3 | 2020 | 8077 | 0.070 |
Why?
|
| Neuroectodermal Tumors | 1 | 2005 | 27 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ret | 3 | 2020 | 220 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2009 | 3920 | 0.070 |
Why?
|
| Endocrine Gland Neoplasms | 2 | 1996 | 25 | 0.060 |
Why?
|
| Sarcoma | 1 | 2017 | 1895 | 0.060 |
Why?
|
| Cysts | 1 | 2010 | 676 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 6030 | 0.060 |
Why?
|
| Risk Factors | 5 | 2020 | 72145 | 0.060 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2009 | 501 | 0.060 |
Why?
|
| Cohort Studies | 9 | 2020 | 40450 | 0.060 |
Why?
|
| Growth Inhibitors | 2 | 1999 | 385 | 0.060 |
Why?
|
| Cattle | 1 | 2010 | 3923 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 4751 | 0.060 |
Why?
|
| Nervous System Neoplasms | 2 | 1996 | 91 | 0.060 |
Why?
|
| Prospective Studies | 14 | 2020 | 53187 | 0.060 |
Why?
|
| Radiography, Interventional | 1 | 1992 | 1095 | 0.060 |
Why?
|
| Prolactinoma | 1 | 2005 | 113 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 1668 | 0.060 |
Why?
|
| Lithium Compounds | 1 | 2005 | 225 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2008 | 595 | 0.060 |
Why?
|
| Diagnostic Imaging | 3 | 2009 | 3507 | 0.060 |
Why?
|
| Genetic Testing | 3 | 2008 | 3439 | 0.060 |
Why?
|
| Health Policy | 1 | 2016 | 2657 | 0.060 |
Why?
|
| Proportional Hazards Models | 4 | 2012 | 12344 | 0.060 |
Why?
|
| Pancreatic Hormones | 1 | 2003 | 13 | 0.060 |
Why?
|
| Physicians | 1 | 2022 | 4554 | 0.060 |
Why?
|
| Adrenal Gland Diseases | 1 | 2004 | 138 | 0.060 |
Why?
|
| Transcription, Genetic | 4 | 2009 | 7721 | 0.060 |
Why?
|
| Models, Educational | 1 | 2006 | 377 | 0.060 |
Why?
|
| Ultrasonography, Doppler | 1 | 2005 | 458 | 0.060 |
Why?
|
| Receptors, Interferon | 1 | 2003 | 115 | 0.060 |
Why?
|
| HLA-A3 Antigen | 1 | 2002 | 34 | 0.060 |
Why?
|
| Blood Specimen Collection | 1 | 2004 | 246 | 0.060 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2003 | 115 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 1670 | 0.060 |
Why?
|
| RNA, Messenger | 6 | 2010 | 13029 | 0.060 |
Why?
|
| Patient Care | 1 | 2009 | 639 | 0.060 |
Why?
|
| Uteroglobin | 1 | 2002 | 57 | 0.050 |
Why?
|
| Radiation Protection | 1 | 2006 | 419 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 9410 | 0.050 |
Why?
|
| Appendicitis | 1 | 1989 | 644 | 0.050 |
Why?
|
| Costs and Cost Analysis | 2 | 2000 | 1679 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2005 | 349 | 0.050 |
Why?
|
| Genes, ras | 1 | 2005 | 691 | 0.050 |
Why?
|
| Abdominal Wall | 1 | 2004 | 155 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 1758 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 14720 | 0.050 |
Why?
|
| Leptin | 1 | 2010 | 1593 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3130 | 0.050 |
Why?
|
| Propionibacterium acnes | 1 | 2002 | 66 | 0.050 |
Why?
|
| Social Stigma | 2 | 2018 | 698 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3236 | 0.050 |
Why?
|
| Emergency Medicine | 1 | 2011 | 1205 | 0.050 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 2867 | 0.050 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2002 | 126 | 0.050 |
Why?
|
| Antimanic Agents | 1 | 2005 | 522 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2007 | 688 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 972 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2017 | 4595 | 0.050 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 2018 | 176 | 0.050 |
Why?
|
| Hyperinsulinism | 1 | 2004 | 415 | 0.050 |
Why?
|
| Endocrine System Diseases | 1 | 2003 | 248 | 0.050 |
Why?
|
| Professional Practice | 1 | 2003 | 326 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 1999 | 1366 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2007 | 728 | 0.050 |
Why?
|
| Frameshift Mutation | 2 | 2000 | 399 | 0.050 |
Why?
|
| Forecasting | 1 | 2010 | 2948 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 433 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2004 | 382 | 0.050 |
Why?
|
| Melanoma | 1 | 1999 | 5462 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2005 | 664 | 0.050 |
Why?
|
| Choristoma | 1 | 2002 | 213 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2021 | 172 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2009 | 1509 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 1901 | 0.050 |
Why?
|
| Disease Progression | 3 | 2017 | 13256 | 0.050 |
Why?
|
| Pediatrics | 1 | 2015 | 3462 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2005 | 554 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2020 | 118 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2005 | 2295 | 0.050 |
Why?
|
| Hospital Bed Capacity | 1 | 2021 | 213 | 0.040 |
Why?
|
| Cachexia | 2 | 2012 | 203 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2013 | 2301 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2002 | 405 | 0.040 |
Why?
|
| Personnel Management | 1 | 2020 | 55 | 0.040 |
Why?
|
| Predictive Value of Tests | 7 | 2016 | 15056 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 5662 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 1107 | 0.040 |
Why?
|
| Transfection | 2 | 1999 | 5892 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2005 | 1659 | 0.040 |
Why?
|
| Organ Size | 1 | 2004 | 2253 | 0.040 |
Why?
|
| Logistic Models | 1 | 2014 | 13403 | 0.040 |
Why?
|
| Apoptosis | 2 | 2007 | 9715 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 1 | 1999 | 257 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2011 | 3678 | 0.040 |
Why?
|
| Esthetics | 1 | 2000 | 306 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2020 | 40955 | 0.040 |
Why?
|
| Peer Review, Health Care | 1 | 2019 | 75 | 0.040 |
Why?
|
| Angiography | 3 | 1997 | 1636 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 2001 | 1144 | 0.040 |
Why?
|
| Contrast Media | 1 | 1992 | 5295 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2021 | 657 | 0.040 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 4187 | 0.040 |
Why?
|
| Pancreatic Polypeptide | 1 | 1997 | 34 | 0.040 |
Why?
|
| Mutation, Missense | 3 | 2008 | 2556 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2018 | 172 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2003 | 5180 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2023 | 866 | 0.040 |
Why?
|
| Staff Development | 1 | 2020 | 223 | 0.040 |
Why?
|
| Pedigree | 2 | 2020 | 4646 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2021 | 371 | 0.040 |
Why?
|
| Signal Transduction | 4 | 2021 | 23387 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2014 | 4440 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 1969 | 0.040 |
Why?
|
| Protein Transport | 1 | 2003 | 1988 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2022 | 652 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 1999 | 2085 | 0.040 |
Why?
|
| Gastrins | 2 | 2009 | 81 | 0.040 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1996 | 37 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2018 | 587 | 0.040 |
Why?
|
| North America | 1 | 2020 | 1249 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2002 | 1038 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2002 | 2615 | 0.040 |
Why?
|
| Necrosis | 1 | 2021 | 1643 | 0.040 |
Why?
|
| H-2 Antigens | 1 | 1997 | 365 | 0.040 |
Why?
|
| Heterozygote | 1 | 2003 | 2790 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 6891 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 2005 | 1340 | 0.030 |
Why?
|
| Feces | 1 | 2022 | 1394 | 0.030 |
Why?
|
| Genes, MHC Class I | 1 | 1997 | 258 | 0.030 |
Why?
|
| Critical Care | 1 | 2009 | 2640 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2018 | 427 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 1052 | 0.030 |
Why?
|
| Certification | 1 | 2019 | 423 | 0.030 |
Why?
|
| Research Design | 1 | 2012 | 5979 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 1997 | 458 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2002 | 1820 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2018 | 546 | 0.030 |
Why?
|
| Clone Cells | 1 | 1999 | 1692 | 0.030 |
Why?
|
| Mammography | 2 | 1997 | 2474 | 0.030 |
Why?
|
| Risk Management | 1 | 2019 | 571 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2018 | 5062 | 0.030 |
Why?
|
| Biliary Tract Neoplasms | 1 | 1997 | 178 | 0.030 |
Why?
|
| Nipples | 1 | 1997 | 216 | 0.030 |
Why?
|
| Receptors, Immunologic | 2 | 1992 | 1423 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2005 | 2924 | 0.030 |
Why?
|
| Axilla | 2 | 2010 | 588 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1999 | 1368 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 9941 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 3 | 2003 | 9274 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2002 | 897 | 0.030 |
Why?
|
| Cell Line | 1 | 2009 | 15994 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1996 | 898 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2023 | 1365 | 0.030 |
Why?
|
| Phenotype | 4 | 2020 | 16331 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2004 | 1195 | 0.030 |
Why?
|
| Injections | 1 | 2017 | 840 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1996 | 316 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2002 | 4438 | 0.030 |
Why?
|
| Mice, Inbred C3H | 2 | 1992 | 964 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2004 | 1361 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 656 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2002 | 1837 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2018 | 435 | 0.030 |
Why?
|
| RNA Splicing | 1 | 1999 | 907 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2009 | 16665 | 0.030 |
Why?
|
| Liposarcoma | 1 | 2017 | 333 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 1167 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2002 | 1252 | 0.030 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 312 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 1350 | 0.030 |
Why?
|
| Voluntary Health Agencies | 1 | 2013 | 39 | 0.030 |
Why?
|
| Endoscopy | 1 | 2003 | 1774 | 0.030 |
Why?
|
| Gene Expression Regulation | 3 | 2007 | 12071 | 0.030 |
Why?
|
| Phenoxybenzamine | 1 | 2012 | 54 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2014 | 256 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2018 | 659 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 1991 | 1581 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 3769 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 351 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2006 | 6191 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 15530 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1996 | 880 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2012 | 174 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1997 | 1470 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 1224 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2014 | 356 | 0.020 |
Why?
|
| APACHE | 1 | 2011 | 277 | 0.020 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2011 | 92 | 0.020 |
Why?
|
| Gait | 1 | 2016 | 784 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 2271 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1459 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2012 | 310 | 0.020 |
Why?
|
| Base Sequence | 2 | 2005 | 12797 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 1992 | 232 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4391 | 0.020 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1992 | 369 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 1991 | 318 | 0.020 |
Why?
|
| Peritonitis | 1 | 1992 | 365 | 0.020 |
Why?
|
| Nuclear Medicine | 1 | 2013 | 233 | 0.020 |
Why?
|
| Hyperplasia | 2 | 2008 | 1183 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 1995 | 1074 | 0.020 |
Why?
|
| Glucagon | 1 | 1992 | 533 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2018 | 2680 | 0.020 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2009 | 84 | 0.020 |
Why?
|
| Portal Vein | 1 | 1991 | 437 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 11472 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2450 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 2009 | 87 | 0.020 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 1288 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 24913 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2012 | 391 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 1991 | 596 | 0.020 |
Why?
|
| Lymphokines | 1 | 1992 | 949 | 0.020 |
Why?
|
| Immunoassay | 2 | 2004 | 752 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2002 | 2986 | 0.020 |
Why?
|
| Mastectomy | 1 | 1997 | 1789 | 0.020 |
Why?
|
| Gene Expression | 3 | 1997 | 7790 | 0.020 |
Why?
|
| Calcitonin | 1 | 2010 | 336 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2023 | 9144 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 689 | 0.020 |
Why?
|
| Social Support | 1 | 2018 | 2117 | 0.020 |
Why?
|
| Adrenal Cortex | 1 | 2009 | 139 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 844 | 0.020 |
Why?
|
| Epinephrine | 1 | 1992 | 793 | 0.020 |
Why?
|
| Cyclin E | 1 | 2009 | 172 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 1992 | 532 | 0.020 |
Why?
|
| Palpation | 1 | 2008 | 166 | 0.020 |
Why?
|
| Biopsy | 2 | 2013 | 6756 | 0.020 |
Why?
|
| Biological Assay | 1 | 1991 | 652 | 0.020 |
Why?
|
| Remission Induction | 1 | 2014 | 2384 | 0.020 |
Why?
|
| DNA Primers | 2 | 2005 | 2892 | 0.020 |
Why?
|
| Quality of Life | 2 | 2022 | 12730 | 0.020 |
Why?
|
| Linear Models | 2 | 2011 | 5948 | 0.020 |
Why?
|
| Cause of Death | 1 | 1998 | 3571 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2010 | 401 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2011 | 19223 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3585 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 1996 | 1699 | 0.020 |
Why?
|
| Binding Sites | 1 | 1996 | 6115 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2007 | 92 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2002 | 10943 | 0.020 |
Why?
|
| Mass Screening | 1 | 2023 | 5238 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 2009 | 268 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7873 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 3391 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 1503 | 0.020 |
Why?
|
| Rats, Inbred F344 | 3 | 1992 | 862 | 0.020 |
Why?
|
| Massachusetts | 1 | 2019 | 8662 | 0.020 |
Why?
|
| Curriculum | 1 | 2019 | 3589 | 0.020 |
Why?
|
| Research | 1 | 2015 | 1999 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 2008 | 547 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 17400 | 0.020 |
Why?
|
| Rabbits | 1 | 1992 | 4886 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 2451 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3151 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 534 | 0.020 |
Why?
|
| Fasting | 1 | 1991 | 1589 | 0.020 |
Why?
|
| Age Factors | 1 | 2002 | 18355 | 0.020 |
Why?
|
| Adrenogenital Syndrome | 1 | 2004 | 1 | 0.020 |
Why?
|
| Vitamin D | 1 | 2019 | 3211 | 0.020 |
Why?
|
| Nomograms | 1 | 2006 | 224 | 0.020 |
Why?
|
| Shock, Septic | 1 | 1991 | 773 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1992 | 1887 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 7901 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2022 | 12695 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2008 | 850 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 697 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 1999 | 14554 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 3862 | 0.010 |
Why?
|
| Caspases | 1 | 2007 | 928 | 0.010 |
Why?
|
| Popliteal Artery | 1 | 1986 | 317 | 0.010 |
Why?
|
| Muscle, Skeletal | 2 | 2012 | 4933 | 0.010 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2004 | 75 | 0.010 |
Why?
|
| Iodide Peroxidase | 1 | 2005 | 293 | 0.010 |
Why?
|
| Aldosterone | 1 | 2008 | 876 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 2876 | 0.010 |
Why?
|
| Boston | 1 | 2016 | 9305 | 0.010 |
Why?
|
| Switzerland | 1 | 2004 | 254 | 0.010 |
Why?
|
| Physical Examination | 1 | 2009 | 1239 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2013 | 6452 | 0.010 |
Why?
|
| Catheterization | 1 | 2008 | 1468 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 18112 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5385 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 2043 | 0.010 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2008 | 602 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 197 | 0.010 |
Why?
|
| Megacolon | 1 | 2002 | 10 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1991 | 1389 | 0.010 |
Why?
|
| Escherichia coli | 2 | 1991 | 4214 | 0.010 |
Why?
|
| Colostomy | 1 | 2002 | 98 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1995 | 4393 | 0.010 |
Why?
|
| Femoral Artery | 1 | 1986 | 843 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 2002 | 267 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2009 | 2713 | 0.010 |
Why?
|
| Informed Consent | 1 | 2008 | 991 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1999 | 10163 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 768 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1997 | 4414 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1994 | 3203 | 0.010 |
Why?
|
| Cecum | 2 | 1992 | 237 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2007 | 3701 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 12705 | 0.010 |
Why?
|
| Ligation | 2 | 1992 | 453 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2002 | 573 | 0.010 |
Why?
|
| Receptors, Interleukin-1 | 2 | 1992 | 261 | 0.010 |
Why?
|
| Frozen Sections | 1 | 2001 | 155 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2011 | 21719 | 0.010 |
Why?
|
| Hirschsprung Disease | 1 | 2002 | 155 | 0.010 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 345 | 0.010 |
Why?
|
| Punctures | 2 | 1992 | 372 | 0.010 |
Why?
|
| Genome | 1 | 2009 | 1803 | 0.010 |
Why?
|
| Caregivers | 1 | 2012 | 2074 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2002 | 792 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 35342 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12242 | 0.010 |
Why?
|
| Comorbidity | 1 | 2014 | 10372 | 0.010 |
Why?
|
| Hoarseness | 1 | 1999 | 65 | 0.010 |
Why?
|
| Homeostasis | 1 | 2010 | 3335 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2638 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2004 | 1849 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2010 | 2896 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2001 | 405 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1999 | 335 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 6474 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 1341 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 1158 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 2502 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2011 | 3679 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2005 | 1221 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2002 | 1866 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1999 | 417 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 1999 | 281 | 0.010 |
Why?
|
| Cytokines | 2 | 2002 | 7317 | 0.010 |
Why?
|
| Infant | 2 | 2015 | 35070 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 2 | 1997 | 6382 | 0.010 |
Why?
|
| Macrophages | 1 | 1992 | 5655 | 0.010 |
Why?
|
| Indium Radioisotopes | 1 | 1996 | 118 | 0.010 |
Why?
|
| Insulin | 1 | 1992 | 6575 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2012 | 8541 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 2006 | 12017 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2002 | 986 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 4982 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2006 | 19862 | 0.010 |
Why?
|
| Isoantigens | 1 | 1999 | 567 | 0.010 |
Why?
|
| Missouri | 1 | 1996 | 116 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 299 | 0.010 |
Why?
|
| Epitopes | 1 | 2002 | 2569 | 0.010 |
Why?
|
| Spleen | 1 | 2002 | 2359 | 0.010 |
Why?
|
| Proteins | 1 | 1991 | 6096 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2015 | 25575 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1997 | 1094 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2002 | 1780 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2002 | 3001 | 0.010 |
Why?
|
| Somatostatin | 1 | 1996 | 459 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 1676 | 0.010 |
Why?
|
| Hospital Charges | 1 | 1996 | 362 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1999 | 2715 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1992 | 18006 | 0.010 |
Why?
|
| Point-of-Care Systems | 1 | 2001 | 1175 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 1992 | 61 | 0.010 |
Why?
|
| Monocytes | 1 | 2002 | 2593 | 0.010 |
Why?
|
| Liver | 2 | 2002 | 7470 | 0.010 |
Why?
|
| Haplotypes | 1 | 1999 | 2781 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 4024 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 5519 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 7141 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1991 | 475 | 0.010 |
Why?
|
| Rats | 3 | 1992 | 24265 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1999 | 2382 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 1999 | 1786 | 0.010 |
Why?
|
| Anesthesia | 1 | 2001 | 1548 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1995 | 1961 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1991 | 297 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1992 | 731 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 5024 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1999 | 3493 | 0.010 |
Why?
|
| Medicare | 1 | 1986 | 6532 | 0.000 |
Why?
|
| Serum Albumin | 1 | 1991 | 674 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1992 | 1791 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1992 | 13019 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1992 | 1458 | 0.000 |
Why?
|
| Drainage | 1 | 1992 | 1140 | 0.000 |
Why?
|
| Peptides | 1 | 1999 | 4392 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1995 | 4771 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1999 | 4379 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 4664 | 0.000 |
Why?
|
| Eating | 1 | 1991 | 1535 | 0.000 |
Why?
|
| Triglycerides | 1 | 1991 | 2450 | 0.000 |
Why?
|
| Body Weight | 1 | 1991 | 4664 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1992 | 8297 | 0.000 |
Why?
|